Clinical outcome and bromodeoxyuridine-derived proliferation indices in 75 invasive breast carcinomas.
BACKGROUND
In vivo labelling of human breast tumours with bromodeoxyuridine (BrdUrd) and analysis by flow cytometry (FCM) allows the labelling index (LI), S phase duration (t(s)) and the potential doubling time (t(pot)) of the tumour to be estimated.


METHODS
The data for a series of tumour specimens from 75 patients with invasive breast carcinoma were reported in 1991, correlated with their lymph-node status, tumour size and grade.


CONCLUSIONS
This study reports the follow-up data over 10 years in respect of time to recurrence and death from the disease. There were no significant correlations between proliferation data and outcome measures. No adverse events were identified which could be attributed to the use of the halogenated pyrimidine label in vivo.
Cutress
R I
RI
Breast and Endocrine Unit, Southampton University Hospitals, Southampton, UK.
Mullee
M A
MA
Royle
G T
GT
Rew
D A
DA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D001973:Bromodeoxyuridine; D002453:Cell Cycle; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D016019:Survival Analysis
D001973:Bromodeoxyuridine